Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma

Next Previous
Trial Profile

Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levonorgestrel (Primary) ; LHRH receptor agonists; Progesterone
  • Indications Adenocarcinoma; Atypical endometrial hyperplasia; Endometrial cancer
  • Focus Therapeutic Use

Most Recent Events

  • 25 Jul 2020 Planned End Date changed from 31 Dec 2020 to 30 Dec 2030.
  • 25 Jul 2020 Planned primary completion date changed from 30 Dec 2019 to 30 Dec 2025.
  • 15 Mar 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top